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Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzymewith a crucial role in themaintenance of genomic stability. In addition
to the role of PARP-1 in DNA repair, multiple studies have also demonstrated its involvement in several inflammatory diseases, such
as septic shock, asthma, atherosclerosis, and stroke, as well as in cancer. In these diseases, the pharmacological inhibition of PARP-1
has shown a beneficial effect, suggesting that PARP-1 regulates their inflammatory processes. In recent years, we have studied the
role of PARP-1 in rheumatoid arthritis, as have other researchers, and the results have shown that PARP-1 has an important function
in the development of this disease. This review summarizes current knowledge on the effects of PARP-1 in rheumatoid arthritis.
1. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease that
is characterized by chronic inflammation that affects the
peripheral joints and leads to the progressive destruction of
the cartilage and bone. RA has a prevalence of 0.5–1% in
the population worldwide, and genetic and environmental
factors have been implicated in its aetiology. The age of onset
is between 35 and 50 years and it is more common in women
than in men (a 3 : 1 ratio), suggesting that hormonal factors
are related to the development of the disease. Approximately
30% of RA patients have extra-articular manifestations,
which contribute to the morbidity and mortality of the
disease. Furthermore, this disease leads to a reduction in life
expectancy between 3 and 10 years [1–4].
In RA, the initiation of an immune response against
unknown antigens leads to the infiltration of the immune
cells, primarily the monocytes/macrophages and B and T
cells in the affected joints, and also to the activation and
proliferation of the stromal cells of the joints, the fibroblast-
like synoviocytes (FLS). The activated immune cells and
FLS release inflammatory mediators, such as cytokines,
chemokines, growth factors, and prostanoids, that perpetuate
the inflammatory process and promote the hyperplasia of
the synovial membrane; they also release matrix metallopro-
teinases (MMPs) and aggrecanases that digest the extracel-
lular matrix and articular structures. These mediators also
contribute to the formation of new blood vessels from the
existing vasculature (angiogenesis), which provide nutrients
to the inflamed joint and allow the infiltration of the immune
cells into the synovium, thereby perpetuating the inflamma-
tory process [4–7].
The final consequences of these processes are the destruc-
tion of the cartilage and the erosion of bone, leading to joint
deformity and disability.
Among the plethora of inflammatory mediators playing
a role in RA, interleukin-1𝛽 (IL-1𝛽), interleukin-6 (IL-6), and
tumour necrosis factor-𝛼 (TNF-𝛼) have been shown to be the
most relevant cytokines in the pathology.These cytokines are
related to different processes in RA, such as the induction
of inflammatory mediators and MMP expression by the
FLS, monocytes/macrophages, and T cells; the activation,
proliferation, and differentiation of the T cells; the induction
of the B cells’ proliferation and antibody production and
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the osteoclast activation. Blocking these cytokines has shown
therapeutic efficacy, and three of the current biological
therapies used for the treatment of RA target these cytokines
[8, 9].
1.1. Molecular Pathways in Rheumatoid Arthritis. Although
there are multiple signal transduction pathways involved in
RA, the mitogen activated protein kinase (MAPK) pathways
play a primary role in the inflammatory processes of the
disease [10, 11]. ERK, JNK, and p38 are expressed and
activated in the synovial tissue of RA patients, and IL-1𝛽 and
TNF-𝛼 induce ERK, p38, and JNK activation in RA FLS [12].
The key role of the MAPKs in RA pathogenesis has been
demonstrated in different studies, in which the absence or
inhibition of MAPKs has been shown to reduce the severity
of several models of arthritis [13–16].
Numerous reports have also shown the activation of
different transcription factors in the synoviumof RApatients,
such as NF-𝜅B, AP-1, IRFs, and FoxO, as well as STAT family
members [17].
NF-𝜅B is activated in the synovial tissue fromRApatients;
both subunits p50 and p65 are located in the nuclei of the
synovial macrophages, and the RA FLS and TNF-𝛼 and
IL-1𝛽 induce a rapid NF-𝜅B translocation in the RA FLS.
Moreover, pharmacological NF-𝜅B inhibition and genetic
NF-𝜅B deletion or modification decrease the severity and
bone erosion in different arthritis models in animals [18, 19].
AP-1 is another transcription factor that is involved
primarily in the process of joint destruction by inducing the
expression of MMPs, but it also elicits other roles in RA,
such as the production of inflammatory mediators and the
induction of T cell differentiation and osteoclast formation.
The key role of AP-1 in RA has been shown in animal models,
in which the deletion or pharmacological inhibition of AP-1
reduces both the severity of arthritis and the production of
inflammatory cytokines and MMPs [17, 20].
1.2. Experimental Arthritis Models. Several experimental
models have been used to characterize the mechanisms
involved in the pathogenesis of arthritis and to test new
therapeutic strategies. Suchmodels include collagen-induced
arthritis (CIA), collagen-antibody-induced arthritis (CAIA),
adjuvant-induced arthritis (AIA), and spontaneous arthritis
models such as TNF-transgenic mice and the K/BxN mice.
The CIA model shares many clinical and histological
features with human RA [21]. Similar to RA, mice develop
symmetric peripheral joint inflammation, synovitis, and
cartilage and bone damage. Mice also develop hyper 𝛾-
globulinemia, antibodies to type-II collagen, and rheumatoid
factor. In this model, DBA/1 mice with theMHC class-II I-Aq
haplotype develop arthritis following the injection of type-
II collagen in complete Freund’s adjuvant (CFA). The initial
injection is usually followed by an intraperitoneal collagen
booster 21 days later. Following immunisation, mice develop
polyarthritis that reaches its severity peak at about day 35
[21–23]. One of the advantages of this model is that it allows
the study of two phases in the development of arthritis: the
initial autoimmune response, in which collagen-specific T
and B cells are produced, and the effector phase, consisting
of joint inflammation, cartilage damage, and bone erosion.
On the other side, a notable disadvantage of this model is
the variable incidence and progression of diseases between
different laboratories. The CIA model has been a valuable
tool to identify the involvement of inflammatory cytokines,
autoantibody responses, and T cells in arthritis and for the
preclinical testing of new treatments for RA [23].
CAIA is a variant of CIA, in which arthritis is induced
by intravenous injection of an arthritogenic cocktail of
monoclonal anti-type-II collagen antibodies [24].Thismodel
reflects only the effector phase of arthritis, which devel-
ops within 48 hours of antibody injection. Clinical and
histopathological features of CAIA are similar to CIA,
although the infiltrate is composed mainly of macrophages
and neutrophils. In addition, the incidence of arthritis
reaches 100% and is independent of the MHC class-II haplo-
type. These two characteristics make this model particularly
useful for studying arthritis in genetically modified mice
[24, 25].
The adjuvant-induced arthritis (AIA) model is elicited
by intradermal injection of CFA at the base of the tail
of rats [26]. AIA is characterized by the rapid onset and
progression of joint inflammation with marked cartilage and
bone resorption. It shares features of human RA including
joint inflammation, cartilage damage, and bone erosion.
However, AIA also affects the spine, the skin, the eyes, and
the gastrointestinal and genitourinary tracts, which are not
involved in human RA [22]. The main advantage of this
model is its reproducibility, as 100% of the animals develop
arthritis by 14 days after inoculation of CFA, and its main
disadvantages are the absence of humoral component and the
dissimilarities with human RA regarding tissue damage.
On the side of the spontaneous arthritis models, the
first developed was the TNF transgenic mouse, which was
reported by Keffer et al. in 1991 [27]. The mice overexpress
human TNF (Tg197) and spontaneously develop an erosive
chronic polyarthritis that closely mimics human RA, with
synovial hyperplasia, pannus formation, cartilage destruc-
tion, and bone erosion. This model has established that TNF
plays a fundamental role in the pathogenesis of RA and it has
been very useful in the assessment of the anti-TNF treatment.
The main limitation of this model is the absence of the early
autoimmune phase of arthritis.
Another widely used spontaneous model is the K/BxN
arthritis model, described by Kouskoff et al. [28]. In this
model, a T cell receptor (TCR) transgene recognizes endoge-
nous glucose-6-phosphate isomerase presented on the MHC
class-II molecule I-Ag7. This autoimmune reaction induces
an early and rapidly progressive arthritis that is T and
B cell dependent and similar to human RA. It is a very
reproducible model in which robust arthritis is developed
in 100% of the transgenic mice. This model allows also
transferring the disease to a large variety of strains using
serum from K/BxN mice, which contains anti-glucose-6-
phosphate isomerase pathogenic antibodies. The advantages
of this model are its reproducibility and the ability to separate
the immunization and effector phases of arthritis [29]. Its
main limitation is that the pathogenic autoantibodies of this
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model are absent in human RA. The K/BxN transfer model
has led to reappreciating the role of the humoral response in
RA pathogenesis.
2. Poly(ADP-ribose) Polymerase-1
Several studies using experimental arthritis models [30–37]
or pharmacological and genetic inhibition of PARP-1 in FLS
from RA patients [38] have revealed the involvement of this
protein in the pathogenesis of arthritis and the potential
therapeutic effects of PARP-1 inhibition.
PARP-1 (EC2.4.2.30) is a nuclear enzyme with a key role
in the maintenance of genomic integrity. PARP-1 is a highly
conserved protein of 113 KDa with a ubiquitous expression
encoded by the PARP-1 gene, located in the human 1q41-42
chromosome. PARP-1 has three primary domains: an amino-
(N-) terminal DNA binding domain (DBD), an automodi-
fication domain, and a carboxy- (C-) terminal catalytic do-
main. PARP-1 is the foundation and themost abundantmem-
ber of the PARP family, which includes 18members. All PARP
members have a characteristic conserved catalytic domain
located in the C-terminal region. According to their func-
tional domains and functions, themembers of the PARP fam-
ily can be divided into five groups: DNA-dependent PARPs,
tankyrases, CCCH-type zinc-finger PARPs, macroPARPs,
and other PARPs [39–41].
PARP-1 is the most important member, exhibiting poly
(ADP-rybosil)ation activity; in fact, 80–85% of this activity is
mediated by PARP-1. The remaining poly(ADP-rybosil)ation
activity is mediated by other members of the family, such as
PARP-2, PARP-3, PARP-4, and tankyrases 1 and 2. Poly(ADP-
rybosil)ation is a protein postransductional modification
essential to cellular processes, such as the regulation of
DNA reparation, themaintenance of chromatin function and
genomic stability, the regulation of transcription, cell cycle
progression, and cell death [39, 41].
In the poly(ADP-rybosil)ation process, PARP cleaves the
NAD+ in the nicotinamide and ADP-ribose to form long
and branched (ADP-ribose) polymers (PAR). The PAR binds
to the acceptor proteins (including PARP-1 itself) through
ester bonds to the residues of carboxyl-𝛾 of glutamic acid
and regulates their enzymatic activity or macromolecular
interactions with other proteins or DNA or RNA molecules
[40, 42].
PARP-1 has a key role in the maintenance of genomic sta-
bility, and the absence or deficiency of PARP-1 leads to defects
in the repair of DNA breaks, an increase in homologous
recombination, sister chromatic exchange, and micronuclei
formation [43]. PARP-1 is also involved in the regulation of
diverse DNA reparation pathways, such as the BER (Base
Excision Repair), SSBR (Single Strand Break Repair), and
DSBR (Double Strand Break Repair) pathways [41, 44, 45].
Moreover, PARP-1 has been related to DNA damage-induced
cell death and apoptosis, both caspase dependent and caspase
independent, and the results suggest that the role of PARP-1
in cell death depends on the cell type and the type of stimulus
[45–50].
2.1. PARP-1 in Inflammation. In recent years, new roles of
PARP-1 have been discovered, and one of the most important
is the role of PARP-1 in inflammatory processes. Different
works have reported that both the pharmacological inhibition
of PARP and a deficiency of PARP-1 have a protective
role in inflammatory diseases, such as LPS-induced sep-
tic shock, uveitis, colitis, streptozotocin-induced diabetes,
asthma-related lung inflammation, and atherosclerosis [33,
51–55]. In these models, PARP inhibition showed an anti-
inflammatory effect, due primarily to a reduction in the
expression of inflammatory mediators, the impaired recruit-
ment of inflammatory cells, the inflammation sites, and the
reduction of necrotic cells in the inflamed areas.
There are two possible molecular mechanisms that have
been proposed to explain this resistance.The first mechanism
is related to the overactivation of the PARP-1 and the
depletion of NAD+ and ATP. In the inflammatory processes,
the oxygen and nitrogen free radicals that are released result
inDNAdamage that leads to the constant activation of PARP-
1 and consequently to the depletion of the cellular levels of
NAD+ and ATP. The depletion of the cellular NAD+ and
ATP pools produces an irreversible cellular energetic failure
and cell death by necrosis. The necrotic cells release their
cellular content into the extracellular space, perpetuating the
inflammatory processes [40, 45, 56].
The second mechanism is related to the role of PARP-
1 as a transcriptional regulator and to the ability of PARP-
1 to modulate the expression of proinflammatory genes,
primarily the cytokines and chemokines. PARP-1 regulates
genomic transcription through 2 independent processes: the
regulation of the chromatin structure and the regulation
of the activity of the transcription factors. In the first
mechanism, PARP-1 mediates the poly(ADP-rybosil-)ation
of the chromatin-associated protein-like histones, leading
to the dissociation of the nucleosomes dissociation and the
relaxation of the chromatin structure. The relaxation of the
chromatin allows the access of proteins implicated in the
transcription into the DNA and the subsequent genomic
expression. PARP-1 also regulates, throughPARP-1 enzymatic
activity, the activation of different transcription factors, such
asNF-𝜅B, AP-1, AP-2, YY-1, Oct-1, Stat-1, B-MYB,HIF-𝛼, and
SP-1.Moreover, PARP-1 alsomodulates the activation of other
transcription factors, including Oct-1, YY-1, B-MYB, and AP-
2, through direct protein-protein interactions [40, 45, 56].
Of special interest is the role of PARP-1 in the transcrip-
tional activation of NF-𝜅B and AP-1, as both transcription
factors are related to different pathologies. PARP-1 regu-
lates the activation of both transcription factors, and PARP
inhibition or PARP-1 deficiency reduces the transcriptional
activity of NF-𝜅B and/or AP-1 in models of septic shock,
inflammation, and ischemic-reperfusion, as well as in cancer
and RA [51, 52, 57–59].
Beyond the modulation of the transcription factors’
activity, PARP-1 has also been related to the regulation of the
MAPKpathways, and it has been shown that PARP inhibition
reduces the activation of ERK, JNK, and p38 in inflammatory
as well as in ischemic and oxidative stress processes [60–63].
Therefore, the protective effect of PARP-1 inhibition in
inflammatory models is due primarily to the reduction of
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Table 1: Effect of PARP inhibition/deletion in experimental arthritis.
Treatment/genetic
approach Arthritis model Major findings Reference
Nicotinamide Potassium peroxochromate-inducedarthritis
Reduced arthritis severity.
Reduction of phagocytic generation of reactive oxygen
species.
[30]
Nicotinic acid amide Collagen-induced arthritis Reduced arthritis severity.Synergistic effect with thalidomide. [31]
INH2BP Collagen-induced arthritis
Reduced arthritis severity and incidence.
Reduced neutrophil infiltration.
Reduced O2 and N2 derived free radical production.
[33]
PJ34 Collagen-induced arthritis
Reduced arthritis severity and incidence.
Reduced neutrophil infiltration.
Reduced O2 and N2 derived free radical production.
[34]
AIQ Collagen-induced arthritis




PARP-1 deficient mice Arthritis induced by anti-collagenantibodies
Reduced arthritis severity.
Reduced synovial inflammation and cartilage damage.
Reduced IL-1𝛽 and MCP-1 expression.
[36]
GPI6150 Adjuvant-induced arthritis Reduced paw edema.Reduced neutrophil infiltration. [37]
the transcription factors and the activation of the signalling
pathways, leading to the downregulation of the expression of
the proinflammatory mediators.
3. PARP-1 in Rheumatoid Arthritis
The studies of the role of PARP-1 in experimental arthritis
models (Table 1) started in the 1990s, using unspecific inhib-
itors such as nicotinamide (NA) and nicotinic acid amide
(NAA). These studies showed that PARP inhibition, alone
or in combination with the TNF-𝛼 inhibitor thalidomide,
reduced the severity of two different models of arthri-
tis, potassium peroxochromate-induced arthritis and the
collagen-induced arthritis (CIA) [30, 31]. However, due to the
high unspecificity of the inhibitors used, the protective role of
PARP inhibition in arthritis could not be concluded in these
studies.
In the late 1990s, the second generation of PARP in-





ide hydrochloride (PJ34), 3,4-dihydro-5-[4-1-(1-piperidinyl)
butoxy]-1-(2H)-isoquinolinone (DPQ), and 4-amino-1, 8-
naphthalimida (ANI), are based on the pharmacophore ben-
zamide (the analogue of NA), and they are very specific and
strong PARP inhibitors [32, 45].
Independent studies have shown that the PARP inhibitors
INH
2
BP and PJ34 reduce the incidence and severity of the
CIA model. Interestingly, the therapeutic effects of both
PARP inhibitors were associated with a reduction in the
oxygen- and nitrogen-derived free radicals and a decrease in
the neutrophil infiltration into the joints [33, 34]. Gonzalez-
Rey et al. [35] also investigated the impact of the PARP-
1 inhibitor AIQ in experimental arthritis. AIQ reduced the
incidence and severity of established collagen-induced arthri-
tis, completely abrogating the joint swelling and destruction
of the cartilage and bone. The therapeutic effect of AIQ was
due to the reduction of the inflammatory response and to the
reduced Th1-driven autoimmune response, demonstrating
the role of PARP-1 in the two crucial processes of RA, the
initiation of the immune response and the initiation and
perpetuation of inflammation [35]. Interestingly, the PARP-
1 inhibitors PJ34 and AIQ also showed a prophylactic effect,
as a protective effect was observed when the inhibitors were
administered after the onset of arthritis.
Our group investigated the impact of the selective sup-
pression of PARP-1, using PARP-1 deficient mice, in a model
of arthritis induced by anti-collagen antibodies (CAIA). We
observed that the absence of PARP-1 reduced the severity
of the disease, although the incidence was not affected. This
reduction was due to the reduced joint expression of the
cytokine IL-1𝛽 and the chemokine MCP-1 (Table 1). Indeed,
we showed that it is likely that PARP-1 is the member of the
PARP family that is involved in arthritic inflammation, as
the reduction in the severity of arthritis was similar in the
arthritic PARP-1 deficient mice regardless of whether they
were treated with the PARP inhibitor DPQ [36].
The role of PARP in arthritis has also been analysed
in other animal models, and comparable results have been
found. Mazzon et al. [37] showed that PARP inhibition by
GPI 6150 treatment significantly reduced paw edema in the
acute and delayed phases of inflammation in the rat adjuvant-
induced arthritis model.
































Figure 1: Effect of PARP-1 on the TNF-𝛼 induced production of inflammatory mediators in RA FLS. TNF-𝛼 stimulation induces the activation
and the translocation to the nucleus of the transcription factors NF-𝜅B and AP-1. In the nucleus, PARP-1 enzymatic activity and/or direct
protein interaction enhances the transcriptional activity of both NF-𝜅B and AP-1, leading to the production of inflammatory mediators.
To extend the knowledge about the role of PARP-1 in
rheumatoid arthritis, our group analysed the effect of PARP
inhibition on the cell proliferation, production of inflamma-
tory mediators, and activation of molecular pathways in the
RA FLS. The results showed that PARP-1 inhibition reduced
the FLS proliferation and the TNF-induced IL-6, IL-8, MCP-
1, RANTES, and MMP-3 production. PARP-1 suppression
by siRNA confirmed the reduction of the production of
the TNF-induced inflammatory mediators, suggesting that
the reduced inflammatory response we observed was due to
the inhibition of poly(ADP-ribosil)ation and not to effects
other than the inhibition of the PARP function. Moreover,
the results also suggest that PARP-1 is the PARP family
member responsible for this reduction. Indeed, in this work
we have suggested that the reductions in the production of
inflammatorymediators and proliferation aremost likely due
to the reduced activation of NF-𝜅B and AP-1, as we observed
a partially impairedNF-𝜅B andAP-1 binding activity after the
treatment with the PARP inhibitors or after the siRNA PARP-
1 transfection (Figure 1) [38].
Therefore, this work supports the previous results in
animal models showing that PARP inhibition reduced the
production of the inflammatory mediators involved in RA.
Taken as a whole, these studies suggest that PARP is
involved in the progression of the inflammatory process of
RA and that the pharmacological inhibition of PARP has an
anti-inflammatory potential in arthritis diseases.
4. PARP-1 Inhibitors in Clinical Trials
Due to the crucial role of PARP-1 in the pathophysiology
of different diseases, multiple clinical trials using PARP
inhibitors have been performed, primarily for the treatment
of cancer. One of the key findings was the discovery of a
potent and specific beneficial effect of PARP inhibition in
BRCA2-deficient tumours, due to the defect in homologous
recombination repair (HRR) in the BRCA2-deficient cells
[64, 65]. In fact, most of the clinical trials using PARP
inhibitors for the treatment of different tumours that have
been performed in the past or are currently being performed
are based on the role of PARP-1 in the maintenance of
genomic stability and integrity. Interestingly, preclinical and
clinical trials have been successful not only in tumours with
deficiencies in the double-stranded DNA repair, such as
mutations in BRCA1 and BRCA2, but also in tumours that
have no defects in the HRR [66–68].
Importantly, a protective effect of PARP inhibition has
also been found in breast cancer through the attenuation
of the NF-𝜅B-mediated signalling, independently of any
defect in the homologous recombination DNA repair. PARP-
1 inhibition may have a clear benefit in tumour treatment
by limiting the rate of cell proliferation and activation of
NF-𝜅B, leading to the suppression of both the inflammation
and the expression of genes related to tumour progression
[69]. These results suggest that PARP inhibitors might also
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be used in other inflammatory diseases in which NF-𝜅B has a
critical role. Moreover, there is preclinical evidence showing
that PARP-1 inhibitors would be beneficial in acute diseases,
such as stroke, traumatic brain injury, circulatory shock, and
acute myocardial infarction, as well as in chronic diseases
such as chronic heart failure and asthma (reviewed byCurtin)
[67].
Two important aspects of the PARP-1 inhibitors for their
use as therapeutic target are the specificity and the toxicity
and tolerability of the inhibitors. Regarding the specificity,
most of the PARP-1 inhibitors that are currently in clinical
trials also inhibit PARP-2 activity, as both PARP-1 and PARP-
2 share significant sequence homology in their catalytic
domains and these PARP inhibitors inhibit the PARP activity
[40, 70]. The inhibition of both PARP-1 and PARP-2, rather
than being a problem, may be beneficial in tumors associated
with defective DNA repair, since PARP-2 is also related to the
maintenance of the genomic stability. Regarding the toxicity
and tolerability of the PARP-1 inhibitors, all the PARP-1
inhibitors which are or have been tested in clinical trial have
not shownunacceptable side effect at the doses used. Alone or
in combination with other drugs, PARP-1 inhibitors showed
mild effects like nausea, vomiting, diarrhea, and fatigue [70–
72].
Therefore, as PARP-1 inhibitors inhibit specifically the
PARP enzymatic activity and are well tolerated for the
patients, clinical trials are really promising and we can expect
the use of PARP inhibitors for the treatment of different
pathologies in the near future.
5. Conclusion
Intensive research on the pathology of RA has stimulated
the introduction of novel approaches aimed at blocking
the inflammatory cytokine pathways in the joint. The best
example is the TNF blockade, which allows at least 20%
improvement in approximately 70% of the patients. However,
as many patients do not respond and remission is rarely
achieved, there is a clear need for identifying novel thera-
peutic strategies. PARP-1, which has been shown to be an
important regulator of inflammation in RA, is an interest-
ing therapeutic target. The use of pharmacological PARP
inhibitors, PARP-1-deficient mice, and siRNA technology
have led to a better understanding of the role of PARP in
arthritis and have indicated the potential therapeutic effects
of PARP inhibition. Specifically, these studies have shown that
PARP-1 is involved in the pathogenesis of RA and that PARP-1
inhibition may be used therapeutically in RA patients.
However, an important aspect of PARP biology that must
be considered in the treatment of chronic diseases such
as RA is the involvement of PARP in the maintenance of
genomic stability. In RA, the long-term inhibition of PARP
might increase the DNA mutation rate, thereby increasing
the probability of tumour development. However, bearing in
mind that the protective effect against arthritis of AIQ in the
CIA model was mediated by a reduction of the autoimmune
response [35], it is also possible to speculate that, in the
future, PARP inhibitors will be developed that induce a strong
diminution of the immune response, leading to the remission
of RA and avoiding the need for chronic treatment.
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[25] K. S. Nandakumar, J. Bäcklund, M. Vestberg, and R. Holmdahl,
“Collagen type II (CII)-specific antibodies induce arthritis in
the absence of T or B cells but the arthritis progression is
enhanced by CII-reactive T cells,”Arthritis Research &Therapy,
vol. 6, no. 6, pp. R544–R550, 2004.
[26] D. L. Asquith, A. M. Miller, I. B. McInnes, and F. Y. Liew,
“Animal models of rheumatoid arthritis,” European Journal of
Immunology, vol. 39, no. 8, pp. 2040–2044, 2009.
[27] J. Keffer, L. Probert, H. Cazlaris et al., “Transgenic mice
expressing human tumour necrosis factor: a predictive genetic
model of arthritis,”EMBO Journal, vol. 10, no. 13, pp. 4025–4031,
1991.
[28] V. Kouskoff, A.-S. Korganow, V. Duchatelle, C. Degott, C.
Benoist, and D. Mathis, “Organ-specific disease provoked by
systemic autoimmunity,” Cell, vol. 87, no. 5, pp. 811–822, 1996.
[29] D. Kyburz and M. Corr, “The KRN mouse model of inflamma-
tory arthritis,” Springer Seminars in Immunopathology, vol. 25,
no. 1, pp. 79–90, 2003.
[30] R. Miesel, M. Kurpisz, and H. Kröger, “Modulation of inflam-
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[34] C. Szabó, L. Virág, S. Cuzzocrea et al., “Protection against
peroxynitrite-induced fibroblast injury and arthritis develop-
ment by inhibition of poly(ADP-ribose) synthase,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 95, no. 7, pp. 3867–3872, 1998.
[35] E. Gonzalez-Rey, R. Martinez-Romero, F. O’Valle et al., “Ther-
apeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor
on experimental arthritis by downregulating inflammation and
Th1 response,” PLoS One, vol. 2, no. 10, Article ID e1071, 2007.
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